经皮冠状动脉介入术（PCI）是目前常见的冠心病的治疗手段之一。血脂管理对于改善PCI术后的长期结局至关重要。冠心病PCI术后降脂药物包括他汀类药物、胆固醇吸收抑制剂、前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂和其他药物。总结了冠心病PCI术后降脂药物的研究进展，分析目前PCI术后药物降脂治疗中面临的挑战，比较不同降脂方案的优劣，探索新型药物的潜力，以期为研究者、医疗行业从业者提供研究思路和启发。

Percutaneous coronary intervention (PCI) is currently one of the common treatment methods for coronary heart disease. Blood lipid management is crucial for improving long-term outcomes after PCI surgery. Post PCI lipid-lowering drugs for coronary heart disease include statins, cholesterol absorption inhibitors, procalcitonin 9 (PCSK9) inhibitors, and other medications. This article summarizes the research progress on lipid-lowering drugs after PCI for coronary heart disease, analyzes the challenges faced in current PCI lipid-lowering treatment, compares the advantages and disadvantages of different lipid-lowering regimens, and explores the potential of new drugs, in order to provide research ideas and inspiration for researchers and medical industry practitioners.

R973

昆明市卫生科技人才培养项目（千工程）[2023-SW（后备）-45]；云南中医药大学校院联合基金项目（XYLH202355）